Results 151 to 160 of about 39,319 (333)
: Ibrutinib is a novel oral therapy that has shown significant efficacy as initial treatment of chronic lymphocytic leukemia (CLL). It is a high-cost continuous therapy differing from other regimens that are given for much shorter courses.
James I. Barnes+6 more
doaj
Ibrutinib has revolutionized the treatment of chronic lymphoid malignancies. Despite its success, ibrutinib has been linked with several reports of invasive fungal infections.
Emily M. Eichenberger+5 more
doaj
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. [PDF]
In the phase 3 RESONATE(TM) study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors.
Brown, JR+29 more
core +1 more source
ABSTRACT Drug‐induced immune reactions are an important burden for patients and health systems. They can be classified into immediate‐drug hypersensitivity reactions (IDHRs) and delayed‐DHRs (DDHRs) based on their phenotype. Drugs do not always behave as allergens and need to bind to proteins, forming adducts.
C. Mayorga+7 more
wiley +1 more source
ABSTRACT The basophil activation test (BAT) is gaining increasing relevance as an ex vivo functional assay in allergy to evaluate IgE‐mediated hypersensitivity reactions to food allergens, venoms, and drugs and to monitor tolerance induction. Establishing universal standard operating protocols has been difficult, due to several challenges including ...
Mariona Pascal+18 more
wiley +1 more source
: The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially.
Jimmy Lee+14 more
doaj
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [PDF]
Ranjana H. Advani+14 more
openalex +1 more source
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
BACKGROUND In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome.
J. Byrd+34 more
semanticscholar +1 more source
The international prognostic index (IPI)‐driven trial inclusion criteria may have contributed to the failure of some of the first‐line trials in large B‐cell lymphoma (LBCL). GLA and LYSA collaborated to improve prognostic stratification in LBCL by analyzing data from trial cohorts and proposed the smIPI.
Umut Yılmaz+24 more
wiley +1 more source
Summary Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T‐cell (CAR‐T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CAR‐T for relapsed/refractory large B‐cell lymphoma. Among 155 patients, 28 (18%) developed AKI with a median time‐to‐
John Sharp+19 more
wiley +1 more source